Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galvus “Approvable” Letter Requests Additional Study In Renal Failure Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Analysts indicate approval of the type 2 diabetes therapy could be delayed for a year or more.
Advertisement

Related Content

Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market
Bristol/AstraZeneca Initiate Phase III Studies Of SGLT-2 Inhibitor Dapagliflozin
Biogen Idec/Elan Plan To Appeal Negative CHMP Opinion Of Tysabri For Crohn’s
Novartis To Resubmit Galvus In Mid-2009
Diabetes Drug Spend Could Rise 70 Percent By 2009, Medco Predicts
Novartis Institutes For Biomedical Research President Mark Fishman: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Janumet Approved; Type 2 Diabetes Therapy Will Be Available By End Of April
Merck’s Januvia Scores European Approval
Gardasil Trial Termination Is More Good News For Merck
Galvus Review Delayed For Safety Analysis Of Primate Skin Data

Topics

Advertisement
UsernamePublicRestriction

Register

PS065681

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel